Kalaris Therapeutics (KLRS) Research & Development (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Research & Development of $7.6 million for Q1 2026, up 4981.88% year-over-year from $149000.0 in Q1 2025, and down 74.78% quarter-over-quarter from $30.0 million in Q4 2025.
Kalaris Therapeutics (KLRS) Research & Development (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $7.6 million for Q1 2026.
- In Q1 2026, Research & Development rose 4981.88% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $38.2 million (down 2.54% YoY), while the FY2025 annual figure was $30.8 million, up 23739.53% from the prior year.
- Research & Development for Q1 2026 stood at $7.6 million, down from $30.0 million in the prior quarter.
- The five-year high for Research & Development was $36.0 million in Q3 2024, with the low at -$210000.0 in Q4 2024.
- The 5-year median for Research & Development is $29.1 million (2022), against an average of $19.4 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development sank 100.63% in 2024, then surged 14398.57% in 2025.
- Kalaris Therapeutics' Research & Development stood at $28.4 million in 2022, then increased by 17.42% to $33.4 million in 2023, then slumped by 100.63% to -$210000.0 in 2024, then soared by 14398.57% to $30.0 million in 2025, then slumped by 74.78% to $7.6 million in 2026.
- Business Quant data shows KLRS's Research & Development at $7.6 million in Q1 2026, $30.0 million in Q4 2025, and $227000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Kalaris Therapeutics | 95.90 Mn | 95.90 Mn | - | 9.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.02 Mn |
| Mar 31, 2026 | 7.57 Mn |
| Dec 31, 2025 | 30.03 Mn |
| Sep 30, 2025 | 227,000.00 |
| Jun 30, 2025 | 350,000.00 |
| Mar 31, 2025 | 149,000.00 |
| Dec 31, 2024 | -210,000.00 |
| Sep 30, 2024 | 36.02 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 20,000.00 |
| Dec 31, 2023 | 33.37 Mn |
| Sep 30, 2023 | 34.16 Mn |
| Jun 30, 2023 | 34.82 Mn |
| Mar 31, 2023 | 30.72 Mn |
| Dec 31, 2022 | 28.42 Mn |
| Sep 30, 2022 | 30.00 Mn |
| Jun 30, 2022 | 31.38 Mn |
| Mar 31, 2022 | 29.07 Mn |
| Dec 31, 2021 | 41.60 Mn |
| Sep 30, 2021 | 33.06 Mn |